Trial of Spesolimab for Generalized Pustular Psoriasis
Mount Sinai researcher shows novel drug significantly improves signs and symptoms of generalized pustular psoriasis—a rare and life-threatening disease
MEDIA ADVISORY
Mount Sinai researcher shows novel drug significantly improves signs and symptoms of generalized pustular psoriasis—a rare and life-threatening disease
Journal: The New England Journal of Medicine
Paper Title: Trial of Spesolimab for Generalized Pustular Psoriasis
Senior Author: Mark Lebwohl, MD, Dean for Clinical Therapeutics, Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai in New York
Background about the condition: Generalized pustular psoriasis (GPP) is a rare, life-threatening skin condition for which there are no approved treatments. It is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus). There is a high unmet need for treatments that can rapidly and completely resolve the signs and symptoms of GPP flares. Flares greatly affect a person’s quality of life and can lead to hospitalization with serious complications, including heart failure, renal failure, sepsis, and death.
What is the paper about: A clinical trial showed that spesolimab is a novel, humanized, selective antibody that blocks the activation of the interleukin-36 receptor
(IL-36R), a signaling pathway within the immune system shown to be involved in the pathogeneses of several autoimmune diseases, including generalized pustula
psoriasis. The novel drug demonstrated rapid clearance of pustules in adult patients with generalized pustular psoriasis (GPP) experiencing a flare.
The study met the primary endpoint, 54% of patients had no visible pustules after a single dose of spesolimab, compared to 6% receiving a placebo at week one
Bottom Line: Spesolimab is rapidly effective in the majority of patients within one week of its first intravenous infusion for patients suffering from generalized pustular psoriasis.
Why the research is important: Generalized pustular psoriasis is a life-threatening condition that compromises the integrity of the skin. Patients are frequently hospitalized and often die from sepsis or other complications, including renal failure, high output cardiac failure, and electrolyte balances.
Mark Lebwohl, MD, said about the study: Generalized pustular psoriasis is a rare life-threatening condition in which the protective functions of the skin are lost, leaving patients vulnerable to loss of electrolytes, nutrients, and fluids for the skin, causing high output cardiac failure, sepsis, and even death. Until now, other treatments used for this condition have not been reliably effective and are often too slow for a condition that is so dangerous. Spesolimab will hopefully be the first approved treatment in the United States for generalized pustular psoriasis, and we will finally have a reliable, rapidly effective treatment for this devastating disease.
Note: FDA has already granted Priority Review, Breakthrough Therapy Designation, and Orphan Drug Designation for Spesolimab.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. The Health System includes approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses across seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, a school of nursing, and schools of medicine and graduate school of biomedical sciences.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York and recognized as one of the world’s top Smart Hospital by Newsweek. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools for National Institutes of Health (NIH) funding and No. 1 among freestanding medical schools, reflecting the strength of its scientific enterprise and leadership in biomedical research.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. To listen to news and stories from Mount Sinai, visit the Mount Sinai Podcast Network.